After acute coronary syndrome, diabetic patients with peripheral vascular disease remain at high risk of cardiovascular events despite secondary prevention measures

Archives of Cardiovascular Diseases

Volumn 103, Issue 2, 2010, Pages 97-105

  Lafitte, Marianne ^a,c   Barandon, Laurent ^a,b,c   Pucheu, Yann ^a,c   Pillois, Xavier ^b,c   Gin, Henri ^a,c   Bonnet, Jacques ^a,b,c   Couffinhal, Thierry ^a,b,c  

^a HAUT LÉVÊQUE HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Coronary artery disease; Diabetes; Patient education; Peripheral vascular disease; Secondary prevention

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYPERTENSIVE AGENT; WARFARIN;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH PROGRAM; HIGH RISK PATIENT; HUMAN; INTERVENTION STUDY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT EDUCATION; PERIPHERAL VASCULAR DISEASE; PRESCRIPTION; SECONDARY PREVENTION;

EID: 77950689095     PISSN: 18752136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.acvd.2009.12.003     Document Type: Article

References (31)

1. Leng GC, Lee AJ, Fowkes FG, et al. Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol 1996;25:1172-1181 (Pubitemid 27013522)
2. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386
3. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol 1999;19:538-545 (Pubitemid 29135153)
4. Chiu JH, Topol EJ, Whitlow PL, et al. Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. Am J Cardiol 2003;92:582-583
5. Cotter G, Cannon CP, McCabe CH, et al. Prior peripheral arterial disease and cerebrovascular disease are independent predictors of adverse outcome in patients with acute coronary syndromes: are we doing enough? Results from the Orbofiban in Patients with Unstable Coronary Syndromes-Thrombolysis In Myocardial Infarction (OPUS-TIMI) 16 study. Am Heart J 2003;145:622-627 (Pubitemid 36403490)
6. Papamichael CM, Lekakis JP, Stamatelopoulos KS, et al. Anklebrachial index as a predictor of the extent of coronary atherosclerosis and cardiovascular events in patients with coronary artery disease. Am J Cardiol 2000;86:615-618
7. Burek KA, Sutton-Tyrrell K, Brooks MM, et al. Prognostic importance of lower extremity arterial disease in patients undergoing coronary revascularization in the Bypass Angioplasty Revascularization Investigation (BARI). J Am Coll Cardiol 1999;34:716-721 (Pubitemid 29436176)
8. Aboyans V, Lacroix P, Postil A, et al. Subclinical peripheral arterial disease and incompressible ankle arteries are both long-term prognostic factors in patients undergoing coronary artery bypass grafting. J Am Coll Cardiol 2005;46:815-820 (Pubitemid 41224804)
9. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;344:1608-1621 (Pubitemid 32479915)
10. Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic InterSociety Consensus; and Vascular Disease Foundation. J Am Coll Cardiol 2006;47:1239-1312
11. NCEP. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 2002;106:3143-3421
12. Smith Jr SC, Allen J, Blair SN, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 2006;113:2363-2372
13. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-1324 (Pubitemid 33015522)
14. Rehring TF, Sandhoff BG, Stolcpart RS, Merenich JA, Hollis Jr HW. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005;41:816-822
15. Bhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 2006;295:180-189 (Pubitemid 43076437)
16. Froehlich JB, Mukherjee D, Avezum A, et al. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Am Heart J 2006;151:1123-1128
17. Steg PG, Bhatt DL, Wilson PW, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA 2007;297:1197-1206
18. Lafitte M, Pradeau V, Leroux L, et al. Efficacy over time of a short overall atherosclerosis management programme on the reduction of cardiovascular risk in patients after an acute coronary syndrome. Arch Cardiovasc Dis 2009;102:51-58
19. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10:S1-10. (Pubitemid 39128338)
20. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008;117:296-329.
21. Graf S, Gariepy J, Massonneau M, et al. Experimental and clinical validation of arterial diameter waveform and intimal media thickness obtained from B-mode ultrasound image processing. Ultrasound Med Biol 1999;25:1353-1363 (Pubitemid 29528375)
22. Grant EG, Benson CB, Moneta GL, et al. Carotid artery stenosis: gray-scale and Doppler US diagnosis - Society of Radiologists in Ultrasound Consensus Conference. Radiology 2003;229:340-346
23. Boulon C, Lafitte M, Richeboeuf V, et al. Prevalence of metabolic syndrome after acute coronary syndrome and its prognostic significance. Am J Cardiol 2006;98:1429-1434 (Pubitemid 44779469)
24. Agnelli G, Cimminiello C, Meneghetti G, Urbinati S. Low ankle-brachial index predicts an adverse 1 -year outcome after acute coronary and cerebrovascular events. J Thromb Haemost 2006;4:2599-2606 (Pubitemid 44741555)
25. Cacoub PP, Abola MT, Baumgartner I, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis 2009;204:e86-92.
26. Bartnik M, Malmberg K, Norhammar A, et al. Newly detected abnormal glucose tolerance: an important predictor of longterm outcome after myocardial infarction. Eur Heart J 2004;25:1990-1997 (Pubitemid 39486017)
27. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-2559
28. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
29. Belch J, MacCuish A, Campbell I, et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a1840.
30. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383-393 (Pubitemid 36159355)
31. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-591 (Pubitemid 351214285)